The 5 linked references in paper D. Romodanovsk P., A. Khokhlov L., A. Miroshnikov E., Д. Ромодановский П., А. Хохлов Л., А. Мирошников Е. (2018) “Планирование и оценка исследований биоэквивалентности препаратов эналаприла // Planning and Evaluation of Bioequivalence Studies of Enalapril Products” / spz:neicon:vedomostincesmp:y:2018:i:4:p:231-237

  1. Ромодановский ДП, Драницына МА, Горячев ДВ, Ниязов РР, Гавришина ЕВ. Планирование дизайна и оценка результатов исследований биоэквивалентности высоковариабельных препаратов на примере розувастатина. Экспериментальная и клиническая фармакология. 2015;78(6):19–25. [Romodanovsky DP, Dranitsyna MA, Goryachev DV, Niyazov RR, Gavrishina EV. Design planning and evaluation of the results of bioequivalence studies of highly variable drugs using rosuvastatin as an example. Eksperimental’naya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology. 2015;78(6):19–25 (In Russ.)] https://doi. org/10.30906/0869-2092-2015-78-6-19-25
  2. Davit BM, Conner DP, Fabian-Fritsch B, Haidar SH, Jiang X, Patel DT, et al. Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications. AAPS J. 2008;10(1):148–56. https://doi.org/10.1208/s12248-008-9015-x
  3. Davit BM, Chen ML, Conner DP, Haidar SH, Kim S, Lee CH, et al. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration. AAPS J. 2012;14(4):915–24. https://doi. org/10.1208/s12248-012-9406-x
  4. Tothfalusi L, Endrenyi L, Arieta AG. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet. 2009;48:725–43. https://doi.org/10.2165/11318040000000000-00000.
  5. Жердев ВП, Колыванов ГБ, Литвин АА, Сариев АК. Гармонизация проведения исследований биоэквивалентности лекарственных препаратов: вопросы и их возможное решение. Экспериментальная и клиническая фармакология. 2003;66(2):60–4. [Zherdev VP, Kolyvanov GB, Litvin AA, Sariev AK. Harmonization of testing drugs for bioequivalence: problems and solutions. Eksperimentalnaya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology. 2003;66(2):60–4 (In Russ.)] https://doi. org/10.30906/0869-2092-2003-66-2-60-64